Hhfexo-M Kid Oral Suspension is a pediatric formulation combining Montelukast (4mg/5ml) and Fexofenadine (30mg/5ml), designed to manage allergic conditions in children. Montelukast, a leukotriene receptor antagonist, works by inhibiting the action of leukotrienes, which are inflammatory mediators involved in asthma and allergic rhinitis, thereby reducing airway inflammation and bronchoconstriction. Fexofenadine, a second-generation antihistamine, selectively blocks peripheral H1 receptors, alleviating symptoms such as sneezing, nasal congestion, and urticaria without causing significant sedation. This dual-action suspension is indicated for the treatment of allergic rhinitis, chronic urticaria, and asthma prophylaxis in pediatric patients, providing symptomatic relief and improving quality of life. The oral suspension form facilitates accurate dosing and ease of administration in children who may have difficulty swallowing tablets. Hhfexo-M Kid Oral Suspension should be used under medical supervision, with dosing adjusted according to age and clinical response. It is generally well tolerated; however, potential side effects include headache, gastrointestinal disturbances, and rare hypersensitivity reactions. Contraindications include hypersensitivity to either active ingredient. Careful monitoring is advised in patients with hepatic impairment or concomitant use of other central nervous system depressants.